

DAFTAR PUSTAKA

1. Coronavirus [Internet]. [cited 2022 Jan 9]. Available from: https://www.who.int/health-topics/coronavirus#tab=tab_1
2. Overview | COVID-19 rapid guideline: managing the long-term effects of COVID-19
| Guidance | NICE.
3. Koc HC, Xiao J, Liu W, Li Y, Chen G. Long COVID and its Management. *Int J Biol Sci* [Internet]. 2022 [cited 2022 Nov 15];18(12):4768. Available from: [/pmc/articles/PMC9305273/](https://pubmed.ncbi.nlm.nih.gov/35429399/)
4. Chen C, Hauptert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. *J Infect Dis* [Internet]. 2022 Nov 1 [cited 2022 Nov 16];226(9). Available from: <https://pubmed.ncbi.nlm.nih.gov/35429399/>
5. The effectiveness of vaccination against long COVID.
6. Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. *JAMA* [Internet]. 2022 Aug 16 [cited 2022 Nov 16];328(7):676–8. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2794072>
7. Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. *EClinicalMedicine* [Internet]. 2022 Nov 1 [cited 2022 Nov 16];53. Available from: <https://pubmed.ncbi.nlm.nih.gov/36051247/>
8. Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. *Nat Med* 2022 288 [Internet]. 2022 Jul 25 [cited 2022

- Nov 16];28(8):1706–14. Available from:
<https://www.nature.com/articles/s41591-022-01909-w>
9. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. *Nat Med* 2021 274 [Internet]. 2021 Mar 10 [cited 2022 Nov 16];27(4):626–31. Available from:
<https://www.nature.com/articles/s41591-021-01292-y>
 10. Endo Mahata L, Lailani M, Rezvi SM, Putra SP, Putra AE. Age and Sex Differences in COVID-19 Clinical Symptom: Analysis of 19,588 Indonesian Cases. *Open Access Maced J Med Sci* [Internet]. 2022 Apr 16 [cited 2022 Nov 16];10(E):643–6. Available from:
<https://oamjms.eu/index.php/mjms/article/view/8709>
 11. Infeksi Emerging Kementerian Kesehatan RI [Internet]. [cited 2022 Nov 16]. Available from:
<https://infeksiemerging.kemkes.go.id/dashboard/COVID-19>
 12. Post COVID-19 condition (Long COVID) [Internet]. [cited 2022 Nov 16]. Available from: <https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition>
 13. Guidance on “Long COVID” as a Disability Under the ADA, Section | HHS.gov [Internet]. [cited 2022 Nov 16]. Available from:
<https://www.hhs.gov/civil-rights/for-providers/civil-rights-covid19/guidance-long-covid-disability/index.html>
 14. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19 [Internet]. [cited 2022 Nov 16]. Available from:
<https://www.medscape.co.uk/viewarticle/covid-19-rapid-guideline-managing-long-term-effects-covid-19-2022a100122v>
 15. Saloner B, Parish K, Julie Ward MA, Grace DiLaura R, Sharon Dolovich J. Persistent Symptoms in Patients After Acute COVID-19. *JAMA* [Internet]. 2020 Aug 11 [cited 2022 Nov 16];324(6):603–5. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2768351>

16. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. *BMJ* [Internet]. 2021 Jul 26 [cited 2022 Nov 16];374. Available from: <https://pubmed.ncbi.nlm.nih.gov/34312178/>
Kim Y, Kim SE, Kim T, Yun KW, Lee SH, Lee E, et al. Preliminary Guidelines for the Clinical Evaluation and Management of Long COVID. <https://www.nature.com/articles/s41591-021-01292-y>
17. Endo Mahata L, Lailani M, Rezvi SM, Putra SP, Putra AE. Age and Sex Differences in COVID-19 Clinical Symptom: Analysis of 19,588 Indonesian Cases. *Open Access Maced J Med Sci* [Internet]. 2022 Apr 16 [cited 2022 Nov 16];10(E):643–6. Available from: <https://oamjms.eu/index.php/mjms/article/view/8709>
18. Infeksi Emerging Kementerian Kesehatan RI [Internet]. [cited 2022 Nov 16]. Available from: <https://infeksiemerging.kemkes.go.id/dashboard/COVID-19>
19. Post COVID-19 condition (Long COVID) [Internet]. [cited 2022 Nov 16]. Available from: <https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition>
20. Guidance on “Long COVID” as a Disability Under the ADA, Section | HHS.gov [Internet]. [cited 2022 Nov 16]. Available from: <https://www.hhs.gov/civil-rights/for-providers/civil-rights-covid19/guidance-long-covid-disability/index.html>
21. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19 [Internet]. [cited 2022 Nov 16]. Available from: <https://www.medscape.co.uk/viewarticle/covid-19-rapid-guideline-managing-long-term-effects-covid-19-2022a100122v>
22. Saloner B, Parish K, Julie Ward MA, Grace DiLaura R, Sharon Dolovich J. Persistent Symptoms in Patients After Acute COVID-19. *JAMA* [Internet]. 2020 Aug 11 [cited 2022 Nov 16];324(6):603–5. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2768351>
23. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms,

- risk factors, and management. *BMJ* [Internet]. 2021 Jul 26 [cited 2022 Nov 16];374. Available from: <https://pubmed.ncbi.nlm.nih.gov/34312178/>
- Kim Y, Kim SE, Kim T, Yun KW, Lee SH, Lee E, et al. Preliminary Guidelines for the Clinical Evaluation and Management of Long COVID.
24. *Infect Chemother* [Internet]. 2022 [cited 2022 Nov 16];54(3):566. Available from: [/pmc/articles/PMC9533168/](https://pubmed.ncbi.nlm.nih.gov/3533168/)
25. Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post- COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? *Lung* [Internet]. 2021 Apr 1 [cited 2022 Nov 16];199(2):113–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/33569660/>
26. Kim Y, Bitna-Ha, Kim SW, Chang HH, Kwon KT, Bae S, et al. Post-acute COVID-19 syndrome in patients after 12 months from COVID-19 infection in Korea. *BMC Infect Dis* [Internet]. 2022 Dec 1 [cited 2022 Nov 16];22(1). Available from: [/pmc/articles/PMC8793328/](https://pubmed.ncbi.nlm.nih.gov/353328/)
27. Zhang X, Wang F, Shen Y, Zhang X, Cen Y, Wang B, et al. Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China. *JAMA Netw Open* [Internet]. 2021 Sep 1 [cited 2022 Nov 16];4(9):e2127403–e2127403. Available from: <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784558>
28. Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post- COVID-19 symptoms 6 months after acute infection among hospitalized and non- hospitalized patients. *Clin Microbiol Infect* [Internet]. 2021 Oct 1 [cited 2022 Nov 16];27(10):1507–13. Available from: <https://pubmed.ncbi.nlm.nih.gov/34111579/>
29. Asadi-Pooya AA, Akbari A, Emami A, Lotfi M, Rostamihosseinkhani M, Nemati H, et al. Risk Factors Associated with Long COVID Syndrome: A

- Retrospective Study. Iran J Med Sci [Internet]. 2021 Nov 1 [cited 2022 Nov 16];46(6):428–36. Available from: <https://pubmed.ncbi.nlm.nih.gov/34840383/>
30. Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mulè G, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect [Internet]. 2022 Apr 1 [cited 2022 Nov 16];28(4):611.e9-611.e16. Available from: <http://www.clinicalmicrobiologyandinfection.com/article/S1198743X21006297/fulltext>
31. Raveendran A V., Jayadevan R, Sashidharan S. Long COVID: An overview. Diabetes Metab Syndr [Internet]. 2021 May 1 [cited 2022 Nov 16];15(3):869. Available from: </pmc/articles/PMC8056514/>
32. Most COVID-19 hospitalizations due to four conditions | National Institutes of Health(NIH) [Internet]. [cited 2022 Nov 16]. Available from: <https://www.nih.gov/news-events/nih-research-matters/most-covid-19-hospitalizations-due-four-conditions>
33. Esenboga S, Ocak M, Akarsu A, Bildik HN, Cagdas D, Iskit AT, et al. COVID-19 in Patients with Primary Immunodeficiency. J Clin Immunol [Internet]. 2021 Oct 1 [cited 2022 Nov 16];41(7):1515–22. Available from: <https://link.springer.com/article/10.1007/s10875-021-01065-9>
34. Desgranges F, Tadini E, Munting A, Regina J, Filippidis P, Viala B, et al. Post-COVID-19 Syndrome in Outpatients: a Cohort Study. J Gen Intern Med [Internet]. 2022 Jun 1 [cited 2022 Nov 16];37(8):1943–52. Available from: <https://link.springer.com/article/10.1007/s11606-021-07242-1>
35. Raveendran A V., Misra A. Post COVID-19 Syndrome (“Long COVID”) and Diabetes: Challenges in Diagnosis and Management. Diabetes Metab Syndr Clin ResRev. 2021 Sep 1;15(5):102235.
36. Pavli A, Theodoridou M, Maltezou HC. Post-COVID Syndrome: Incidence, Clinical Spectrum, and Challenges for Primary Healthcare

- Professionals. Arch Med Res. 2021 Aug 1;52(6):575–81.
37. Umesh A, Pranay K, Pandey RC, Gupta MK. Evidence mapping and review of long-COVID and its underlying pathophysiological mechanism. Infection [Internet]. 2022 Oct 1 [cited 2022 Nov 16];50(5):1053. Available from: [/pmc/articles/PMC9055372/](#)
 38. Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science (80-) [Internet]. 2022 Mar 11 [cited 2022 Nov 16];375(6585):1122–7. Available from: <https://www.science.org/doi/10.1126/science.abm8108>
 39. Marik PE, Iglesias J, Varon J, Kory P. A scoping review of the pathophysiology of COVID-19. Int J Immunopathol Pharmacol [Internet]. 2021 [cited 2022 Nov 16];35:1–16. Available from: [/pmc/articles/PMC8477699/](#)
 40. The different types of COVID-19 vaccines [Internet]. [cited 2022 Nov 16]. Available from: <https://www.who.int/news-room/feature-stories/detail/the-race-for-a-covid-19-vaccine-explained>
 41. Vaksin Dashboard [Internet]. [cited 2022 Nov 16]. Available from: <https://vaksin.kemkes.go.id/#/vaccines>
 42. Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: The status and perspectives in delivery points of view. Adv Drug Deliv Rev [Internet]. 2021 Mar 1 [cited 2022 Nov 16];170:1. Available from: [/pmc/articles/PMC7759095/](#)
 43. Speiser DE, Bachmann MF. COVID-19: Mechanisms of Vaccination and Immunity. Vaccines 2020, Vol 8, Page 404 [Internet]. 2020 Jul 22 [cited 2022 Nov 16];8(3):404. Available from: <https://www.mdpi.com/2076-393X/8/3/404/htm>
 44. The Oxford/AstraZeneca (ChAdOx1-S [recombinant] vaccine) COVID-19 vaccine: what you need to know [Internet]. [cited 2022 Nov 16].

Available from: <https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know>

45. The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know [Internet]. [cited 2022 Nov 16]. Available from: <https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know>
46. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* [Internet]. 2021 Feb 4 [cited 2022 Nov 16];384(5):403–16. Available from: [/pmc/articles/PMC7787219/](https://pubmed.ncbi.nlm.nih.gov/37764344/)
47. The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you need to know [Internet]. [cited 2022 Nov 16]. Available from: <https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19-vaccine-what-you-need-to-know>
48. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* [Internet]. 2020 Dec 31 [cited 2022 Nov 16];383(27):2603–15. Available from: <https://pubmed.ncbi.nlm.nih.gov/33301246/>
49. The Sinopharm COVID-19 vaccine: What you need to know [Internet]. [cited 2022 Nov 16]. Available from: <https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know>
50. The Sinovac-CoronaVac COVID-19 vaccine: What you need to know [Internet]. [cited 2022 Nov 16]. Available from: <https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know>
51. Mohammed I, Nauman A, Paul P, Ganesan S, Chen KH, Jalil SMS, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review.

- Hum Vaccin Immunother [Internet]. 2022 [cited 2022 Nov 16];18(1). Available from: [/pmc/articles/PMC8862168/](#)
52. Shinde V, Bhikha S, Hoosain Z, Archary M, Borhat Q, Fairlie L, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med [Internet]. 2021 May 20 [cited 2022 Nov 16];384(20):1899–909. Available from: <https://www.nejm.org/doi/10.1056/NEJMoa2103055>
53. CDC, Ncird. Pfizer-BioNTech COVID-19 Vaccine Vaccine Dosage Chart. 2022 [cited 2022 Nov 16]; Available from: <https://www.fda.gov/>
54. The Novavax vaccine against COVID-19: What you need to know [Internet]. [cited 2022 Nov 16]. Available from: <https://www.who.int/news-room/feature-stories/detail/the-novavax-vaccine-against-covid-19-what-you-need-to-know>
55. Definition of vaccinated and unvaccinated for COVID-19 deaths - Office for National Statistics [Internet]. [cited 2022 Nov 16]. Available from: <https://www.ons.gov.uk/aboutus/transparencyandgovernance/freedomofinformationfoi/definitionofvaccinatedandunvaccinatedforcoivd19deaths>
56. Fully Vaccinated vs. Partially Vaccinated | Everything You Need To Know | Medicspot [Internet]. [cited 2022 Nov 16]. Available from: <https://www.medicspot.co.uk/health-guides/covid-19/fully-vaccinated-vs-partially-vaccinated>
57. What is a COVID-19 vaccine booster? [Internet]. [cited 2022 Nov 16]. Available from: <https://portal.ct.gov/vaccine-portal/Vaccine-Knowledge-Base/Articles/What-Is-A-Booster-Shot>
58. Winpenny EM, Winkler MR, Stochl J, Van Sluijs EMF, Larson N, Neumark-Sztainer D. Associations of early adulthood life transitions with changes in fast food intake: A latent trajectory analysis. Int J Behav Nutr Phys Act [Internet]. 2020 Oct 9 [cited 2023 Jun 17];17(1):1–11. Available from: <https://ijbnpa.biomedcentral.com/articles/10.1186/s12966-020->

01024-4

59. Vanichkachorn G, Newcomb R, Cowl CT, Murad MH, Breeher L, Miller S, et al. Post-COVID-19 Syndrome (Long Haul Syndrome): Description of a Multidisciplinary Clinic at Mayo Clinic and Characteristics of the Initial Patient Cohort. *Mayo Clin Proc* [Internet]. 2021 Jul 1 [cited 2022 Nov 16];96(7):1782–91. Available from: <http://www.mayoclinicproceedings.org/article/S0025619621003566/fulltext>
60. Long COVID Comorbidities: Endocrine, Metabolic, Neuropsychiatric, Muscle, Cardiovascular, Pulmonary, Dermatologic Dysfunctions - Full Text View - ClinicalTrials.gov [Internet]. [cited 2022 Nov 16]. Available from: <https://clinicaltrials.gov/ct2/show/NCT05293366>
61. Rumain B, Schneiderman M, Geliebter A. Prevalence of COVID-19 in adolescents and youth compared with older adults in states experiencing surges. *PLoS One* [Internet]. 2021 Mar 1 [cited 2023 Jun 12];16(3):e0242587. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242587>
62. Blomberg B, Mohn KGI, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, et al. Long COVID in a prospective cohort of home-isolated patients. *Nat Med* [Internet]. 2021 Sep 1 [cited 2023 Jun 17];27(9):1607–13. Available from: <https://pubmed.ncbi.nlm.nih.gov/34163090/>
63. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol* 2023 213 [Internet]. 2023 Jan 13 [cited 2023 May 30];21(3):133–46. Available from: <https://www.nature.com/articles/s41579-022-00846-2>
64. Cysique LA, Jakabek D, Bracken SG, Allen-Davidian Y, Heng B, Chow S, et al. The kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC. *Ann Clin Transl Neurol* [Internet]. 2023

- Jun 15 [cited 2023 Jun 18]; Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.51825>
65. Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS- CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. *Brain Behav Immun*. 2022 Jul 1;103:154–62
 66. Ayoubkhani D, Bosworth ML, King S, Pouwels KB, Glickman M, Nafilyan V, et al. Risk of Long COVID in People Infected With Severe Acute Respiratory Syndrome Coronavirus 2 After 2 Doses of a
 67. Long COVID Comorbidities: Endocrine, Metabolic, Neuropsychiatric, Muscle, Cardiovascular, Pulmonary, Dermatologic Dysfunctions - Full Text View - ClinicalTrials.gov [Internet]. [cited 2022 Nov 16]. Available from: <https://clinicaltrials.gov/ct2/show/NCT05293366>
 68. Romain B, Schneiderman M, Geliebter A. Prevalence of COVID-19 in adolescents and youth compared with older adults in states experiencing surges. *PLoS One* [Internet]. 2021 Mar 1 [cited 2023 Jun 12];16(3):e0242587. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242587>
 69. Blomberg B, Mohn KGI, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, et al. Long COVID in a prospective cohort of home-isolated patients. *Nat Med* [Internet]. 2021 Sep 1 [cited 2023 Jun 17];27(9):1607–13. Available from: <https://pubmed.ncbi.nlm.nih.gov/34163090/>
 70. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol* 2023 213 [Internet]. 2023 Jan 13 [cited 2023 May 30];21(3):133–46. Available from: <https://www.nature.com/articles/s41579-022-00846-2>
 71. Cysique LA, Jakabek D, Bracken SG, Allen-Davidian Y, Heng B, Chow S, et al. The kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC. *Ann Clin Transl Neurol* [Internet]. 2023

- Jun 15 [cited 2023 Jun 18]; Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.51825>
72. Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS- CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. *Brain Behav Immun*. 2022 Jul 1;103:154–62.
 73. Ayoubkhani D, Bosworth ML, King S, Pouwels KB, Glickman M, Nafilyan V, et al. Risk of Long COVID in People Infected With Severe Acute Respiratory Syndrome Coronavirus 2 After 2 Doses of a
 74. Coronavirus Disease 2019 Vaccine: Community- Based, Matched Cohort Study. *Open forum Infect Dis* [Internet]. 2022 Sep 2 [cited 2023 Jun 17];9(9). Available from: <https://pubmed.ncbi.nlm.nih.gov/36168555/>
 75. Self-reported long COVID after infection with the Omicron variant in the UK - Office for National Statistics [Internet]. [cited 2023 Jun 17]. Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidafterinfectionwiththeomicronvariant/6may2022>
 76. Kuodi P, Gorelik Y, Zayyad H, Wertheim O, Wiegler KB, Abu Jabal K, et al. Association between BNT162b2 vaccination and reported incidence of post-COVID- 19 symptoms: cross-sectional study 2020-21, Israel. *npj Vaccines* 2022 71 [Internet]. 2022 Aug 26 [cited 2023 Jun 12];7(1):1–8. Available from: <https://www.nature.com/articles/s41541-022-00526-5>
 77. Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J. The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID. *Vaccines* 2022, Vol 10, Page 652 [Internet]. 2022 Apr 21 [cited 2023 May 30];10(5):652. Available from: <https://www.mdpi.com/2076-393X/10/5/652/htm>
 78. Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V,

Zaccardi F, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. *BMJ* [Internet]. 2022 [cited 2023 Jun 17];377. Available from: <https://pubmed.ncbi.nlm.nih.gov/35584816/>

79. Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. *npj Vaccines* 2021 6(1):1–13. [Internet]. 2021 Aug 16 [cited 2023 Jun 17];6(1):1–13. Available from: <https://www.nature.com/articles/s41541-021-00369-6>

